IMAGE: Lung squamous cell carcinoma

Breaking News

Key: Meeting M      Journal J      Funder F

Showing releases 76-100 out of 1284.

<< < 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 > >>

Public Release: 25-Apr-2016
Canadian Medical Association Journal
Expand HPV vaccination programs in Canada to include males
Expanding human papillomavirus (HPV) vaccination programs to include males in Canada will help protect them against HPV-related cancers, according to an analysis published in CMAJ.

Contact: Kim Barnhardt
kim.barnhardt@cmaj.ca
613-520-7116 x2224
Canadian Medical Association Journal

Public Release: 25-Apr-2016
Nature Cell Biology
Chronic inflammation leads to imbalanced blood system and potentially cancer risk
A study in Nature Cell Biology shows that chronic exposure to interleukin-1 causes HSCs to produce cells needed to fight infection and repair injury, but at the expense of their own ability to self-renew and maintain a healthy blood system. Elevated interleukin-1 (IL-1) accompanies the chronic inflammation associated with human conditions including obesity, diabetes and autoimmune disorders.
National Institutes of Health

Contact: Garth Sundem
garth.sundem@ucdenver.edu
University of Colorado Anschutz Medical Campus

Public Release: 25-Apr-2016
Addiction
Top tobacco control experts to FDA: Studies of e-cigs suggest more benefit than harm
Seven top international tobacco control experts are prompting regulators at the US Food and Drug Administration to have a broad 'open-minded' perspective when it comes to regulating vaporized nicotine products, especially e-cigarettes.
NIH/National Institute on Drug Abuse

Contact: Karen Teber
km463@georgetown.edu
Georgetown University Medical Center

Public Release: 25-Apr-2016
Nature Neuroscience
Researchers find potential new treatment target for deadly brain cancer
A team of researchers has found a key player in brain tumor formation that may lead to new therapies for a deadly and incurable cancer. The study published in Nature Neuroscience is the first to show that a protein called OSMR (Oncostatin M Receptor) is required for glioblastoma tumours to form. Glioblastoma is one of the most deadly cancers, resistant to radiation, chemotherapy and difficult to remove with surgery.
Canadian Institutes for Health Research, National Institutes of Health, Mathers Foundation, The Ottawa Hospital Foundation

Contact: Amelia Buchanan
ambuchanan@ohri.ca
61-379-855-557-3687
Ottawa Hospital Research Institute

Public Release: 25-Apr-2016
Nature Neuroscience
Key mechanism identified in brain tumor growth
A gene known as OSMR plays a key role in driving the growth of glioblastoma tumors, according to a new study led by a McGill University researcher and published in the journal Nature Neuroscience.
US National Institutes for Health, Canadian Institutes for Health Research, Mathers Foundation, Canada Research Chairs program

Contact: Chris Chipello
christopher.chipello@mcgill.ca
514-398-4201
McGill University

Public Release: 25-Apr-2016
JAMA Pediatrics
For some cancers, risk lower among kids of non-US-born Hispanic mothers
The children of Hispanic mothers not born in the United States appeared to have a lower risk for some types of childhood cancers, according to an article published online by JAMA Pediatrics.

Contact: Peter Bracke
PBracke@mednet.ucla.edu
310-206-4430
The JAMA Network Journals

Public Release: 22-Apr-2016
Transplantation
Organ recipients with previous cancers linked to higher death rates, new cancers
People who had cancer before receiving an organ transplant were more likely to die of any cause, die of cancer or develop a new cancer than organ recipients who did not previously have cancer, a new paper has found.
Canadian Institutes of Health Research

Contact: Leslie Shepherd
shepherdl@smh.ca
416-864-6094
St. Michael's Hospital

Public Release: 22-Apr-2016
Alimentary Pharmacology and Therapeutics
Risk of liver cancer from hepatitis B persists even after clearing the virus
Long-term infection with hepatitis B virus (HBV) can cause liver inflammation and increase the risk of liver cancer. Researchers from the US Centers for Disease Control and Prevention, however, found that resolving HBV infection was not associated with reduced rates of liver cancer.

Contact: Penny Smith
sciencenewsroom@wiley.com
44-012-437-70448
Wiley

Public Release: 22-Apr-2016
Nature
Cell death mechanism may -- paradoxically -- enable aggressive pancreatic cells to live on
The most aggressive form of pancreatic cancer -- often described as one of the hardest malignancies to diagnose and treat -- thrives in the presence of neighboring tumor cells undergoing a particular form of 'orchestrated cell death.' This is according to a major study from researchers at NYU Langone's Perlmutter Cancer Center and recently published in the journal Nature.
German Research Foundation, National Pancreas Foundation, Pancreatic Cancer Action Network, Lustgarten Foundation, National Institutes of Health

Contact: Jim Mandler
jim.mandler@nyumc.org
212-404-3525
NYU Langone Medical Center / New York University School of Medicine

Public Release: 22-Apr-2016
Angewandte Chemie
Successful laboratory test of photoswitchable anti-tumor agent
Photoswitchable agents might reduce side effects of a chemotherapy. So far, photodynamic therapies have been dependent on oxygen in the tissue. But hardly any oxygen exists in malignant, rapidly growing tumors. A group of researchers of KIT and the University of Kiev has now developed a photo-switchable molecule as a basis of an oxygen-independent method. Their successful laboratory tests on tumors are reported in the journal Angewandte Chemie.

Contact: Monika Landgraf
presse@kit.edu
49-721-608-47414
Karlsruher Institut für Technologie (KIT)

Public Release: 22-Apr-2016
Journal of the National Cancer Institute
Estrobolome disparities may lead to developing biomarkers that could mitigate cancer risk
Investigating disparities in the composition of the estrobolome, the gut bacterial genes capable of metabolizing estrogens in both healthy individuals and in women diagnosed with estrogen-driven breast cancer may lead to the development of microbiome-based biomarkers that could help mitigate the risk of certain cancers, according to a review paper published April 22 in the JNCI: Journal of the National Cancer Institute.
NIH/National Cancer Institute, Shifrin-Myers Breast Cancer Discovery Fund, NIH/National Institute of Diabetes and Digestive and Kidney Diseases, and Diane Belfer Program for Human Microbial Ecology

Contact: Molly Grote
molly.grote@oup.com
212-743-8337
Oxford University Press USA

Public Release: 21-Apr-2016
JAMA Oncology
No risk association observed for anthracycline chemotherapy, cognitive decline
New data analyses found no association between anthracycline chemotherapy and greater risk of cognitive decline in breast cancer survivors, according to an article published online by JAMA Oncology.

Contact: Peter M. Bracke
PBracke@mednet.ucla.edu
310-206-4430
The JAMA Network Journals

Public Release: 21-Apr-2016
JAMA Oncology
No increased risk of fatal CV events for breast cancer patients on newer hormone therapy
In a new study from Kaiser Permanente, researchers found the use of aromatase inhibitors, hormone-therapy drugs used to treat patients with breast cancer, was not associated with an increased risk of fatal cardiovascular events, including heart attacks or stroke, compared with tamoxifen, another commonly prescribed anti-cancer drug that works on hormones and which has been associated with a serious risk of stroke.
California Breast Cancer Research Program, NIH/National Cancer Institute

Contact: Navneet Miller
navneet.miller@creation.io
415-262-5972
Kaiser Permanente

Public Release: 21-Apr-2016
Cell
Researchers identify new mechanism to target 'undruggable' cancer gene
RAS genes are mutated in more than 30 percent of human cancers and represent one of the most sought-after cancer targets for drug developers. A new study published in the April 20 issue of the journal Cell by researchers at the Icahn School of Medicine at Mount Sinai led by E. Premkumar Reddy, Ph.D., has identified a new mechanism for targeting this important cancer gene.
Onconova Therapeutics Inc, National Institutes of Health

Contact: Lucia Lee
newsmedia@mssm.edu
646-605-5940
The Mount Sinai Hospital / Mount Sinai School of Medicine

Public Release: 21-Apr-2016
Journal of the National Cancer Institute
Young adult survivors of childhood cancer report feeling middle-aged
Do survivors of childhood cancer return to normal health as they grow up? New research from Dana-Farber/Boston Children's Cancer and Blood Disorders Center and Harvard T.H. Chan School of Public Health finds young adult survivors of childhood cancer , age 18-29, report health-related quality of life that resembles that of adults, 40-49, in the general population, according to a study in the Journal of the National Cancer Institute.
NIH/National Cancer Institute, American Lebanese-Syrian Associated Charities

Contact: Irene Sege
irene.sege@childrens.harvard.edu
617-919-7379
Dana-Farber Cancer Institute

Public Release: 21-Apr-2016
Cell
Wellderly study suggests link between cognitive decline genes and healthy aging
An eight-year-long accrual and analysis of the whole genome sequences of healthy elderly people, or 'Wellderly,' has revealed a higher-than-normal presence of genetic variants offering protection from cognitive decline, researchers from the Scripps Translational Science Institute reported today in the journal Cell.
Scripps Health, Complete Genomics, Inova Health System, Odeen family, Gary and Mary West Foundation, Lavin Family Foundation

Contact: Keith Darce
darce.keith@scrippshealth.org
858-678-7121
Scripps Health

Public Release: 21-Apr-2016
JCI Insight
Critical immunotherapy target marks dysfunctional regulatory T cells in brain cancer
In this issue of JCI Insight, David Hafler and colleagues at Yale University and Massachusetts Institute of Technology report that PD-1 expression on regulatory T cells from the tumors of glioblastoma multiforme patients correlates with regulatory T cell dysfunction.
National Institutes of Health, Koch Institute, NIH/National Institute of Neurological Disorders and Stroke, Nancy Taylor Foundation for Chronic Diseases Inc., National Science Foundation

Contact: Corinne Williams
press_releases@the-jci.org
Journal of Clinical Investigation

Public Release: 21-Apr-2016
Current Biology
The cell copying machine: How daughters look like their mothers
Tiny structures in our cells, called centrioles, control both cell division and motility. The number of these structures is highly monitored, with deviations causing infertility, microcephaly and cancer. A research team, from Instituto Gulbenkian de Ciencia, led by Monica Bettencourt-Dias, uncovered the mechanism by which mother cells know that they provide the right number of centrioles to their daughters, in a study now published in the scientific journal Current Biology.
Fundação para a Ciencia e a Tecnologia, European Molecular Biology Organization, European Research Council

Contact: Vanessa Borges
vborges@igc.gulbenkian.pt
Instituto Gulbenkian de Ciencia

Public Release: 21-Apr-2016
American Association for Cancer Research 2016 Annual Meeting
eLife
VCU Massey researchers uncover process that drives prostate cancer metastasis
Researchers at VCU Massey Cancer Center have uncovered a novel function of the gene PLK1 (polo-like kinase 1) that helps prostate cancer cells metastasize (spread) to other parts of the body. This mechanism highlights new potential targets for cancer therapies and challenges the previous understanding of PLK1's role in cancer growth and progression.
American Cancer Society, NIH/National Cancer Institute, National Institutes of Health

Contact: John Wallace
wallacej@vcu.edu
804-628-1550
Virginia Commonwealth University

Public Release: 21-Apr-2016
JCI Insight
Identification of therapeutic targets in multiple myeloma
In this issue of JCI Insight, Yoichi Imai and colleagues at Tokyo Women's Medical University in Tokyo, Japan, demonstrate that multiple myeloma cells express high levels of the protein phosphatase PPP3CA, a subunit of the signaling protein calcineurin, which can be targeted by the drug FK506.
Japan Society for the Promotion of Science, Takeda Science Foundation, International Myeloma Foundation Japan Grant, Japan Leukemia Research Fund

Contact: Corinne Williams
press_releases@the-jci.org
Journal of Clinical Investigation

Public Release: 21-Apr-2016
eLife
New insights in how blood vessels increase their size
A new study from the group of Holger Gerhardt in collaboration with Katie Bentley's Lab addresses a long standing question in the wider field of developmental biology and tissue patterning in general, and in the vascular biology field in particular: 'What are the fundamental mechanisms controlling size and shape of tubular organ systems?'

Contact: Sooike Stoops
sooike.stoops@vib.be
32-924-46611
VIB (the Flanders Institute for Biotechnology)

Public Release: 20-Apr-2016
Cancer Microenvironment
Stomach cancer diagnostics: New insights on stage of tumor growth
Researchers of Kazan Federal University and the National Academy of Sciences of Ukraine found correlations between the superoxide and nitric oxide generation rates, levels of active forms of MMP-2 and MMP-9 in tumor and adjoining tissues between each other and with the disease stages for gastric cancer patients.

Contact: Yevgeniya Litvinova
press@kpfu.ru
7-843-233-7345
Kazan Federal University

Public Release: 20-Apr-2016
Nature
UMN researchers show 'dirty mice' could clean up immune system research
Scientists at the University of Minnesota have developed a new way to study mice that better mimics the immune system of adult humans and which could significantly improve ways to test potential therapeutics. Published online today in the journal Nature, the researchers describe the limitations of laboratory mice for immunology research and reveal the benefits of what they are calling 'dirty mice.'
National Institutes of Health

Contact: Caroline Marin
crmarin@umn.edu
612-624-5680
University of Minnesota Academic Health Center

Public Release: 20-Apr-2016
JAMA Oncology
Detecting when the most common skin cancer turns dangerous
A team of researchers who specialize in treating cancers of the eye wanted to identified EZH2 as a marker for aggressive basal cell skin cancer. It may also provide a potential target for treatment.
National Institutes of Health, Genentech, Research to Prevent Blindness, NIH/National Eye Institute

Contact: Nicole Fawcett
nfawcett@umich.edu
734-764-2220
University of Michigan Health System

Public Release: 20-Apr-2016
Science Translational Medicine
Study finds explanation for some treatment-resistant breast cancers
The new study led by Vanderbilt-Ingram Cancer Center investigators has identified gene alterations that may explain why triple-negative breast cancer is resistant to most existing treatments, and suggests that a targeted therapy currently in clinical development may prove beneficial.
IBC Network Foundation, US Department of Defense, and NIH/National Cancer Institute

Contact: Craig Boerner
craig.boerner@vanderbilt.edu
615-322-4747
Vanderbilt University Medical Center

Showing releases 76-100 out of 1284.

<< < 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 > >>

  Search News Releases

     

 

EurekAlert!